REFERENCES
1. Miyake CY, Asaki SY, Webster G, et al. Circadian variation of ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia. JACC Clin Electrophysiol 2017;3:1308-17.
2. Peltenburg PJ, Kallas D, Bos JM, et al. An international multicenter cohort study on β-blockers for the treatment of symptomatic children with catecholaminergic polymorphic ventricular tachycardia. Circulation 2022;145:333-44.
3. Miyake CY, Webster G, Czosek RJ, et al. Efficacy of implantable cardioverter defibrillators in young patients with catecholaminergic polymorphic ventricular tachycardia: success depends on substrate. Circ Arrhythm Electrophysiol 2013;6:579-87.
4. Roston TM, Jones K, Hawkins NM, et al. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: a systematic review. Heart Rhythm 2018;15:1791-9.
5. De Ferrari GM, Dusi V, Spazzolini C, et al. Clinical management of catecholaminergic polymorphic ventricular tachycardia: the role of left cardiac sympathetic denervation. Circulation 2015;131:2185-93.
6. Ko DT, Hebert PR, Coffey CS, et al. Adverse effects of beta-blocker therapy for patients with heart failure: a quantitative overview of randomized trials. Arch Intern Med 2004;164:1389-94.
7. Medeiros-Domingo A, Bhuiyan ZA, Tester DJ, et al. The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading frame mutational analysis. J Am Coll Cardiol 2009;54:2065-74.
8. Leenhardt A, Denjoy I, Guicheney P. Catecholaminergic polymorphic ventricular tachycardia. Circ Arrhythm Electrophysiol 2012;5:1044-52.
9. Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003;113:829-40.
10. Kannankeril PJ, Mitchell BM, Goonasekera SA, et al. Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy. Proc Natl Acad Sci USA 2006;103:12179-84.
11. Chelu MG, Sarma S, Sood S, et al. Calmodulin kinase II-mediated sarcoplasmic reticulum Ca2+ leak promotes atrial fibrillation in mice. J Clin Invest 2009;119:1940-51.
12. Pan X, Philippen L, Lahiri SK, et al. In vivo Ryr2 editing corrects catecholaminergic polymorphic ventricular tachycardia. Circ Res 2018;123:953-63.
13. Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 2020;38:824-44.
14. Quick AP, Wang Q, Philippen LE, et al. SPEG (striated muscle preferentially expressed protein kinase) is essential for cardiac function by regulating junctional membrane complex activity. Circ Res 2017;120:110-9.
15. Werfel S, Jungmann A, Lehmann L, et al. Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase. Cardiovasc Res 2014;104:15-23.
16. Yue Y, Pan X, Hakim CH, et al. Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. Hum Mol Genet 2015;24:5880-90.
17. Moore OM, Ho KS, Copeland JS, Parthasarathy V, Wehrens XHT. Genome editing and cardiac arrhythmias. Cells 2023;12:1363.
18. Xie C, Zhang YP, Song L, et al. Genome editing with CRISPR/Cas9 in postnatal mice corrects PRKAG2 cardiac syndrome. Cell Res 2016;26:1099-111.
19. Johansen AK, Molenaar B, Versteeg D, et al. Postnatal cardiac gene editing using CRISPR/Cas9 with AAV9-mediated delivery of short guide RNAs results in mosaic gene disruption. Circ Res 2017;121:1168-81.
20. Liu Y, Wang R, Sun B, et al. Generation and characterization of a mouse model harboring the exon-3 deletion in the cardiac ryanodine receptor. PLoS One 2014;9:e95615.
21. Zou Y, Liang Y, Gong H, et al. Ryanodine receptor type 2 is required for the development of pressure overload-induced cardiac hypertrophy. Hypertension 2011;58:1099-110.
22. Zheng J, Dooge HC, Pérez-Hernández M, et al. Preserved cardiac performance and adrenergic response in a rabbit model with decreased ryanodine receptor 2 expression. J Mol Cell Cardiol 2022;167:118-28.
23. Loaiza R, Benkusky NA, Powers PP, et al. Heterogeneity of ryanodine receptor dysfunction in a mouse model of catecholaminergic polymorphic ventricular tachycardia. Circ Res 2013;112:298-308.
24. Sun B, Yao J, Ni M, et al. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med 2021;13:eaba7287.
25. Gao WD, Perez NG, Marban E. Calcium cycling and contractile activation in intact mouse cardiac muscle. J Physiol 1998;
26. Kong X, Belbachir N, Zeng W, et al. Generation of two induced pluripotent stem cell lines from catecholaminergic polymorphic ventricular tachycardia patients carrying RYR2 mutations. Stem Cell Res 2023;69:103111.
27. Lee RG, Mazzola AM, Braun MC, et al. Efficacy and safety of an investigational single-course CRISPR base-editing therapy targeting PCSK9 in nonhuman primate and mouse models. Circulation 2023;147:242-53.
28. Bidasee KR, Dinçer UD, Besch HR Jr. Ryanodine receptor dysfunction in hearts of streptozotocin-induced diabetic rats. Mol Pharmacol 2001;60:1356-64.
